Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03180333
Recruitment Status : Completed
First Posted : June 8, 2017
Last Update Posted : June 8, 2017
Sponsor:
Information provided by (Responsible Party):
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Brief Summary:
Conduct in Chinese healthy adult subjects:1.To observe the safety and tolerability of multiple-dose oral administration of different doses of PNA;2.By measuring the changing drug concentration in the plasma and urine after a single oral administration of different doses of PNA on the condition of fasting, the pharmacokinetic parameters of the single dose are estimated;3.By measuring the changing drug concentration in the plasma of PNA after a multiple-dose oral administration on the condition of fasting, the pharmacokinetic parameters of multiple-dose are estimated, and a basis for dosage regimens of the clinical research phase Ⅱ is provided;4.To study the effects of diet on the pharmacokinetic parameters via the changes of concentration of PNA in plasma after high-fat and high-calorie food.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis B Drug: PNA Drug: PNA placebo Phase 1

Detailed Description:

The study is divided into three parts:

  1. The tolerance test of randomized,double-blind, placebo-controlled multiple-dose oral administrations.2 dosage groups are set up.Each group contains 8 subjects,evenly composed of men and women.The beginning dosage of the study is 160mg/L.Subjects who have successfully completed tests of the beginning dosage group and passed the safety assessment will enter the test of next dosage group(320mg/L) according to the same method.
  2. Pharmacokinetic tests(single/multiple dose) .(1)Single dosing pharmacokinetic tests.36 eligible healthy subjects are selected. Each group has 12 people, evenly composed of men and women. After taking 80mg/160mg/320mg of PNA orally in fasting state, blood and urine samples are taken to be tested and analyzed, in order to study the pharmacokinetic characteristics of single-dose administrations.(2)Multiple dosing pharmacokinetic tests.In the single-dose administration trial, respectively choose 10 subjects (evenly composed of men and women) in middle and high-dose group (160mg qd、320mg qd).After the single-dose administration,inspecte the pharmacokinetic characteristics with 6-day continuous administration. Blood samples are taken to test the trough drug concentration of pre-dose in the morning of the 3rd, 4th, 5th day after administration, and the 6th morning before and after the administration, to study the steady state concentration and the fluctuation coefficient of the trough to peak drug concentration after multiple-dose, and to find out whether there exists the effect of drug storage and / or induction of drug enzyme.
  3. The effect of diet.Choose 12 qualified healthy subjects (normally evenly composed of men and women), a randomized two-way cross-over design is used, respectively orally take 160 mg of PNA before and after meal, and to study the effect of diet on pharmacokinetic via blood collection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers
Study Start Date : March 2012
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PNA 1
Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;
Drug: PNA
Other Name: Metacavir Enteric-coated Capsules

Placebo Comparator: PNA placebo
Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days
Drug: PNA placebo
Other Name: Metacavir Enteric-coated Capsules placebo

Experimental: PNA 2
Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;
Drug: PNA
Other Name: Metacavir Enteric-coated Capsules

Experimental: PNA 3
Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;
Drug: PNA
Other Name: Metacavir Enteric-coated Capsules

Experimental: PNA 4
The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.
Drug: PNA
Other Name: Metacavir Enteric-coated Capsules




Primary Outcome Measures :
  1. TEAEs [ Time Frame: day 1 to day 14 ]
    Frequency of treatment-emergent adverse events


Secondary Outcome Measures :
  1. AUC [ Time Frame: day 1 to day 7 ]
    Area under the plasma concentration versus time curve of PNA

  2. Cmax [ Time Frame: day 1 to day 7 ]
    Maximum Plasma Concentration of PNA

  3. T1/2 [ Time Frame: day 1 to day 7 ]
    The time required while plasma concentration is reduced by half of PNA



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy volunteers aged 18 to 45 years old ;
  2. Body mass index (BMI) above/equal 19 and below 24 kg/m2;
  3. Child bearing potential, has a negative serum pregnancy test at screening period, and agrees to use contraceptions consistently and correctly in 14 days after dosing;
  4. Subjects with no cardiovascular, liver, kidney, digestive tract, nervous and mental and other acute or chronic diseases that may affect the safety and pharmacokinetic of drug;
  5. Signed informed consent voluntarily.

Exclusion Criteria:

  1. Subjects not meet the inclusion criteria;
  2. Abnormal clinically significant laboratory results;
  3. Abnormal clinically significant electrocardiogram (ECG);
  4. A positive hepatitis B surface antigen, hepatitis C or HIV test result;
  5. History of hypersensitivity or allergy to any of the study drugs or to drugs of similar chemical classes;
  6. Addicted to smoking and drinking;
  7. Drink in 36 hours before post-dosing of study drug;
  8. Ingest any foods or beverages which may affect pharmacokinetics;
  9. Drug abuse,a history of poisoning;
  10. Subjects who had received other medications within 2 weeks prior to the first administration of Investigational Product,and the original and main metabolites were not completely eliminated ;
  11. Subjects who participated in any other clinical trials within 3 months prior to the first administration of Investigational Product;
  12. Subjects who had suffered from hemorrhage or blood donation over 200ml will be excluded;
  13. Subjects over exercised accompanied with fatigue and muscle aches within 1 week period to the first administration of Investigational Product;
  14. Children,women who are pregnant,lactating,with childbearing potential and who are using acyeterions;
  15. Subjects in the opinion of the investigator, could not participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03180333


Locations
Layout table for location information
China, Jiangsu
Nanjing First Hospital
Nanjing, Jiangsu, China
Sponsors and Collaborators
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Investigators
Layout table for investigator information
Principal Investigator: Hongwei Fan The First Affiliated Hospital with Nanjing Medical University
Principal Investigator: Ruifang Wang The First Affiliated Hospital with Nanjing Medical University
Layout table for additonal information
Responsible Party: Guangzhou Yipinhong Pharmaceutical CO.,LTD
ClinicalTrials.gov Identifier: NCT03180333    
Other Study ID Numbers: PNA-20120309-V1
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: June 8, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Guangzhou Yipinhong Pharmaceutical CO.,LTD:
Chronic Hepatitis B
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis B
Hepatitis B, Chronic
Hepatitis
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Infections
Blood-Borne Infections
Communicable Diseases
Hepadnaviridae Infections
DNA Virus Infections